life scienc diagnost industri offer attract
growth moat wari valuat
page full analyst note
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
water leadership liquid chromatographi mass
spectrometri market give compel inher competit
edg -- compani larg instal base instrument gener
high consum util benefit sticki base
enjoy greater portion sale high margin consum
higher exposur biopharma market close peer
agil addit greater product sophist
liquid chromatographi make product sell
consider higher price point ga chromatographi
water greater exposur biopharma market also
enabl higher growth rel peer need lc/m lead
biolog molecul research character led high
demand product past year
trend expect continu although slower pace
estim biolog custom segment grown nearli
low-double-digit annual pace last decad
repres custom base
water growth under-perform expect recent
anticip exposur china new product innov
remain key growth driver busi believ
weak stem part under-perform
thermal analysi segment tougher year-over-year comp
biopharma busi like modest market share loss
competitor like agil step lc-m product
offer although manag mistim product refresh
cycl view compani biotof mass spectromet
develop launch instanc cater
specif develop qualiti analysi need
biopharma custom help compani regain
foot meanwhil sale china percentag revenu
doubl last decad repres
close total sale despit grow concern tariff
affect chines custom purchas still anticip healthi
demand sophist high-perform product
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
water provid analyt instrument pharmaceut biochem
industri custom water lead liquid chromatographi market
account roughli total revenu remain sale come
thermal analysi instrument instrument consum informat
servic account approxim sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
life scienc diagnost industri offer attract
growth moat wari valuat
think plenti like life scienc
sever competit advantag lead econom
moat industri tend predict
attract growth outlook especi area
bioprocess analyt instrument genom
addit somewhat insul broader
macroeconom cycl nearli everi compani life
scienc diagnost manufactur coverag also earn
econom moat thank intang often pair
high switch cost valuat alreadi reflect
optim howev multipl across industri
look expens view current think water
agil becton dickinson reflect best
valu trade close territori view mettler
biomerieux significantli overvalu
moat common life scienc tool thank intang
switch cost gener award moat life
scienc diagnost firm record consist
innov larg instal base equip
dedic pull consum
chromatographi mass spectrometri market led
water agil creat one wide-moat
segment benefit low disrupt risk high
barrier entri comfort oligopoli razor-and-
blade busi model high custom switch cost
nich ga
outlook life scienc diagnost market
remain stabl attract pocket growth
estim market exce roughli billion grow
nearli annual depend market
segment popul growth increas drug research
volum workflow improv rise manufactur
qualiti standard emerg field genet research
test key industri growth driver
complet overview life scienc moat analysi
pleas see report life scienc diagnost industri
offer attract growth econom moat wari
valuat discuss growth outlook
econom moat life scienc industri
slightli lower fair valu estim per
share make slight reduct
value/ebitda price/adjust earn multipl
approxim time
although anticip recent sale progress
biopharma market slow time still view water
exposur higher growth market new product
launch exposur china long-term posit
mid-single-digit growth rate come year driven
mostli lc-m segment forecast low-single-digit
growth thermo analysi divis
also forecast stabl profit
dont anticip competit
issu materi shift product mix dramat
alter compani margin assumpt result
return invest capit continu rang
estim compani cost
capit
give water medium uncertainti rate thank
rel high barrier entri moder switch cost
mostli stabl product evolut chromatographi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
high switch cost help lock custom
long-term replac cycl custom base
scientist util instrument face steep
learn curv sizabl up-front invest util
special highli sensit equip
market scientist often remain loyal supplier ensur
sampl protect standard minim
consum lc/m machin larg
stick product primari lc column due
compani high manufactur qualiti product
innov avoid lose valuabl data risk
third-parti product water sell nearli mani
origin ubondpak lc column late
higher perform standard new instrument often
lead higher consum attach rate water
launch ultraperform liquid chromatographi uplc
column creat demand instrument materi
perform criteria run higher pressur
instrument user therefor stick
compani column uplc wherea substitut higher
hplc categori
water extens exposur biopharma market
enabl instrument consum becom
engrain drug-manufactur process includ
brand gener small molecul drug manufactur
well total biopharma custom segment
compos revenu give
compani near quarter market share categori
estim research use one platform earli
stage drug develop regul requir
instrument drug life-cycle last
year chang manufactur includ
test impur etc would requir approv
regul agil thermo fisher
uptak firm new product steadi price
greater-than-expect perform oversea lead
high-single-digit annual growth nearli
margin expans nearli within five year thank
price power oper leverag optimist
assumpt lead fair valu estim
reflect price-to-earnings multipl approxim
bear-cas scenario fair valu estim
oper margin fall roughli basi point
five year scenario assum increas
price pressur market share loss competit
addit overal slowdown biopharma spend
lc/m equip scenario valu busi
believ wide moat thank larg
compani leadership liquid chromatographi mass
drive adopt compani instrument platform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
shimadzu primari competit
instrument reagent market tend
incorpor high level technolog complex
also keep barrier entri somewhat high opinion
addit challeng manufactur reliabl
complex instrument think necessari servic
compon
consult repair present hurdl new entrant
establish reput brand
market
water industri lead profit return capit
reflect compani wide moat oper margin
return invest capit excess
last decad respect among highest
life scienc diagnost industri
stabl moat trend view compet
rel stabl market think risk disrupt
technolog low lc/m market rel matur
compani innov lc/m equip
consum continu attract custom grow
instal base machin keep switch cost high
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
owat high perform instrument remain
standard high-perform applic especi
pharma regulatori limit preserv
strategi preserv return capit near
top industri manag prefer focus
core area rather pursu acquisit
dilut return
oemerg market benefit increas
market presenc gener drugmak
increas food safeti environment test
chines govern
oth compani face formid competit ms
like thermo fisher agil market
share slip somewhat past year
competitor activ new
owith nearli sale pharma academ
govern custom lack diversif
mani larger peer compani therefor
expos potenti neg market cycl
owat -base manufactur expos
compani foreign exchang risk
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
clean balanc sheet
invest exceed compani debt balanc
last decad end water
nearli billion debt dwarf nearli billion
cash invest although could take
significantli debt given firm stabl cash flow
manag avoid larg transact
instead return capit sharehold share
repurchas earli board director
author billion share repurchas program
target three-year period compani
give water medium uncertainti rate thank
rel high barrier entri moder switch cost
mostli stabl product evolut chromatographi
sheet afford compani plenti flexibl water
equip sale increas exposur macroeconom
condit especi among industri custom
compani larg revenu contribut consum
biopharma custom make busi somewhat
insul spend cycl also
reduc relianc pharma custom top
pharma custom account sale
make one third busi
govern research spend fairli
spend among govern academ custom water
also focus busi oper competit
environ despit smaller thermal analysi segment
consid water essenti pure-play lc/m
market competitor larger diversifi
organ establish competitor new entrant
introduc better product develop stronger relationship
custom compani may lose market share well
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
abil extract price increas moreov
compani compet mani larger rival invest
signific resourc core busi requir
maintain technolog edg regardless larg
liquid chromatographi mass spectrometri busi
seem larg immun disrupt technolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
board
maintain exemplari stewardship rate
somewhat concern manag product
pipelin competitor like agil seem
gain share thank innov product
regardless think econom moat remain
strong evidenc industri lead profit
return capit also think manag disciplin
capit alloc strategi preserv high return
repres date owner name posit common share held report holder issuer
share
fund
execut turnov last
year envis major strateg shift
busi chri connel former presid
restor therapi group replac
dougla berthiaum ceo oconnel also
replac berthiaum chairman board
sherri buck becam cfo previou financi
execut experi libbey connel
inherit busi profit return capit
nearli highest industri anticip
compani still follow disciplin capit alloc
strategi far manag follow similar footstep
develop effort return capit sharehold
share repurchas
predecessor
focus
share
fund
think execut team fairli align
sharehold interest insid ownership particularli
larg total compens heavili weight toward
long-term incent base rel total sharehold
return short-term incent base revenu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
think water agil deserv wide moat
look fairli valu
updat moat rate fair valu estim
agil slightli lower
fair valu estim per share follow
modestli disappoint result last quarter
continu favor outlook compani
wide moat meanwhil upgrad agil moat
wide base firm nearli equal size liquid
chromatographi busi well leadership ga
chromatographi weve slightli bump agil fair
valu estim base extend second stage
model moat chang new fair valu
estim reflect impli time forward adjust
earn multipl compani
compani look fairli valu current market price
think worth investor keep name
thank sophist analyt requir
custom switch cost feel
agil innov disciplin capit alloc
strategi deserv wide moat agil lead gc
market -- share quit high switch
cost lc market -- also come close second
place behind water lc
expect agil sustain return capit
near averag respect long
term chromatographi mass spec market
fairli matur industri forecast slightli higher growth
adjust oper margin expans
agil compani continu benefit new
product launch like intuvo gc ultivo lc-m
exposur higher growth diagnost market combin
manufactur effici effort meanwhil
forecast near growth new product like
expect launch biotof help refresh
weak share fairli valu oct
water perform third quarter weaker
expect compani slightli lower full-year
guidanc top line earn anticip
advers trend persist remaind year
anticip lower growth forecast slightli
impact fair valu estim overli signific
bake growth moder go
share fairli valu current level reiter
wide moat rate firm
water top line constant currenc
compani continu under-perform industri peer
particularli mass spec side compani
admit late product refresh cycl pharma
spend grew constant currenc pharma
particularli europ rein spend sever
year strong expans ta segment also deliv
sequenti weaker result albeit attribut time
order nonetheless segment bright star
water year help mask rel
weak core divis geographi
 bounc back slightli quarter europ
particularli pharma rough quarter china
doubl digit yet india look soft spot
rest year
firm gross oper margin line
expect compani adjust oper
expens except research develop
 line softer revenu growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
water deliv better perform rais fve
water perform second quarter larg
expect rais fair valu estim per
share mainli due cash flow realis sinc last
report share fairli valu current level
reiter wide moat rate firm
water top line constant currenc rebound
weak first-quart result mass spectrometri
main culprit under-perform first quarter
improv sequenti high-resolut mass spec sale
remain soft pharma spend grew constant currenc
pharma seemingli rein spend
sever year strong expans ta segment
rejuven continu quarter segment
larg respons growth industrial/
appli end market revitalis ta product portfolio
result year-to-d double-digit growth heel
growth ta strong perform help
mask rel weak core divis
declin revenu quarter
larg due deceler biomed research
aforement larg pharma soft china
quarter offset flat result india compani
recur revenu stream support mid-
single-digit top-lin full-year guidanc forecast
despit instrument sale roughli flat far
firm gross oper margin show good year-
over-year improv line expect
compani updat earn guidanc rang
align forecast
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
